CJC-1295 NO DAC 5 mg + IPA 5

CJC-1295 NO DAC, also known as Modified GRF(1-29), is a synthetic analogue of growth hormone-releasing hormone (GHRH) investigated for its interaction with the GHRH receptor. Ipamorelin is a synthetic pentapeptide studied for its activity at the ghrelin receptor, GHS-R1a. Together, these compounds provide researchers with two distinct molecular approaches for investigating the growth-hormone signaling axis. This presentation contains 5 mg of CJC-1295 NO DAC and 5 mg of Ipamorelin, supplied as a combined research material for qualified laboratory environments. The blend may be relevant to research involving peptide pharmacology, receptor signaling, growth-hormone-axis biology, and related cellular pathways.

Key Features

5 mg CJC-1295 NO DAC 5 mg Ipamorelin CJC-1295 NO DAC / Modified GRF(1-29) Ipamorelin / GHS-R1a research peptide Two distinct peptide components targeting different signaling pathways Suitable for controlled laboratory research Relevant to growth-hormone-axis and receptor pharmacology studies Intended for in-vitro and preclinical research workflows Research Focus CJC-1295 NO DAC and Ipamorelin are studied as distinct components of the growth-hormone signaling system. CJC-1295 NO DAC is associated with GHRH-receptor research, while Ipamorelin is investigated through the ghrelin/GHS-R1a receptor pathway. Current literature does not establish clinical efficacy for the marketed combination, making laboratory research and analytical characterization important contexts for this material.

Important Notice

This product is supplied strictly for research and laboratory use. It is not intended for human or veterinary use, self-administration, consumption, diagnosis, treatment, or prevention of disease. This research material should be handled only by appropriately qualified personnel in accordance with applicable laboratory protocols and regulations